BSETrident Texofab LtdMediumNeutral
Announced Sat, 31 May · 17:51 IST

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the quarter and Year ended March 31, 2025

Mgmt Guided Margin PressureInvestor Communications View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab, a Surat-based semi-composite textile manufacturer, reported its Q4 and FY25 results via an earnings presentation. FY25 revenue grew 23% YoY to ₹12,205.62 lakhs, while Q4FY25 revenue rose 27% YoY to ₹3,820.63 lakhs. However, FY25 EBITDA fell to ₹547.20 lakhs from ₹615.57 lakhs, with EBITDA margins contracting sharply from 6.19% to 4.48%, which management acknowledged as moderation. Profit after tax more than doubled to ₹251.01 lakhs in FY25 from ₹107.98 lakhs, helped by a strong Q4 PAT of ₹51.05 lakhs versus a loss in Q4FY24. Shareholders' fund nearly tripled to ₹4,723.87 lakhs, reflecting a recent capital infusion, and management reiterated its focus on manufacturing, which now contributes 63.6% of revenue.

Likely market impact

Revenue growth is healthy but the sharp drop in EBITDA margins and rising interest costs (₹454.98 lakhs in FY25 vs ₹403.69 lakhs) signal profitability pressure despite higher sales. Shareholders may weigh top-line momentum against eroding margins and increased finance costs in the near term.